Morpholino

MO2-ptger2a

ID

ZDB-MRPHLNO-060302-2

Name

MO2-ptger2a

Previous Names

ep2-MO2 (1)
MO2-ptger2l (1)

Target

ptger2a (1)

Sequence

5' - ACTGTCAATACAGGTCCCATTTTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

translation blocker targeted to start codon

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO2-ptger2a

Expressed Gene	Anatomy	Figures
slc12a1	pronephric distal early tubule	Fig. 4 from Poureetezadi et al., 2016
slc12a3	pronephric distal late tubule	Fig. 4 from Poureetezadi et al., 2016

Phenotype

Phenotype resulting from MO2-ptger2a

Phenotype	Fish	Figures
pronephric distal early tubule slc12a1 expression increased distribution, abnormal	TU + MO2-ptger2a	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule increased size, abnormal	TU + MO2-ptger2a	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal	TU + MO2-ptger2a	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule decreased size, abnormal	TU + MO2-ptger2a	Fig. 4 from Poureetezadi et al., 2016

Phenotype of all Fish created by or utilizing MO2-ptger2a

Phenotype	Fish	Conditions	Figures
pronephric distal late tubule slc12a3 expression decreased distribution, abnormal	TU + MO2-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule slc12a1 expression increased distribution, abnormal	TU + MO2-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal early tubule increased size, abnormal	TU + MO2-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
pronephric distal late tubule decreased size, abnormal	TU + MO2-ptger2a	standard conditions	Fig. 4 from Poureetezadi et al., 2016
exocrine pancreas size, ameliorated	WT + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression decreased distribution, abnormal	WT + MO1-ptger2a + MO2-ptger2a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	WT + MO1-ptger2a + MO2-ptger2a	control	Fig. 2 from Nissim et al., 2014
hematopoietic stem cell decreased amount, abnormal	WT + MO1-ptger2a + MO2-ptger2a	standard conditions	Fig. S1 from North et al., 2007
exocrine pancreas prss1 expression amount, ameliorated	WT + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
liver EGFP expression decreased distribution, abnormal	as3Tg + MO1-ptger2a + MO2-ptger2a	control	Fig. 1 from Nissim et al., 2014
liver size, ameliorated	as3Tg + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptger2a + MO2-ptger2a	control	Fig. 1 from Nissim et al., 2014
liver EGFP expression amount, ameliorated	as3Tg + MO1-ptger2a + MO2-ptger2a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression decreased distribution, abnormal	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas prss1 expression amount, ameliorated	WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 1 from Nissim et al., 2014
liver decreased size, abnormal	as3Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 1 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	zf578Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	control	Fig. 2 from Nissim et al., 2014
exocrine pancreas decreased size, abnormal	zf578Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a	chemical treatment: prostaglandin E2	Fig. 2 from Nissim et al., 2014

Citations